Evidence map›Paper›PMID 26950368›Full record

ArticleNature structural & molecular biology2016

Diverse functions of myosin VI elucidated by an isoform-specific α-helix domain.

Hans-Peter Wollscheid, Matteo Biancospino, Fahu He, Elisa Magistrati, Erika Molteni, Michela Lupia, Paolo Soffientini, Klemens Rottner, Ugo Cavallaro, Uberto Pozzoli and 3 more

Open access · greenAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The twoFrontiers in physiology · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Diverse functions of myosin VI in spermiogenesis.Histochemistry and cell biology · 2021
    Review
  13. Article
  14. Unconventional Myosins: How Regulation Meets Function.International journal of molecular sciences · 2019
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Hans-Peter Wollscheid *Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milan 20139, Italy.
Matteo Biancospino *Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milan 20139, Italy.
Fahu He *Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Elisa MagistratiFondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milan 20139, Italy.
Erika MolteniComputational Biology, Scientific Institute IRCCS E.MEDEA, Bosisio Parini 23842, Italy.
Michela LupiaMolecular Medicine Program, European Institute of Oncology, Milan 20141, Italy.
Paolo SoffientiniFondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milan 20139, Italy.
Klemens RottnerHelmholtz Centre for Infection Research, 38124 Braunschweig, Germany.
Ugo CavallaroMolecular Medicine Program, European Institute of Oncology, Milan 20141, Italy.
Uberto PozzoliComputational Biology, Scientific Institute IRCCS E.MEDEA, Bosisio Parini 23842, Italy.
Marina MapelliDepartment of Experimental Oncology, European Institute of Oncology, Milan 20139, Italy.
Kylie J WaltersCenter for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Simona PoloFondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milan 20139, Italy.
IFOM · ITEuropean Institute of Oncology · ITFrederick National Laboratory for Cancer Research · USIRCCS Eugenio Medea · ITHelmholtz Centre for Infection Research · DEUniversity of Milan · IT

Funding

Myosin VI: a new ubiquitin receptorZIABC011627 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WALTERS, KYLIE · 2015 to 2025
$4.6M
Intramural NIH HHSWorldwide Cancer Research 11-0051
6 · The paper itself

Abstract

Myosin VI functions in endocytosis and cell motility. Alternative splicing of myosin VI mRNA generates two distinct isoform types, myosin VI(short) and myosin VI(long), which differ in the C-terminal region. Their physiological and pathological roles remain unknown. Here we identified an isoform-specific regulatory helix, named the α2-linker, that defines specific conformations and hence determines the target selectivity of human myosin VI. The presence of the α2-linker structurally defines a new clathrin-binding domain that is unique to myosin VI(long) and masks the known RRL interaction motif. This finding is relevant to ovarian cancer, in which alternative myosin VI splicing is aberrantly regulated, and exon skipping dictates cell addiction to myosin VI(short) in tumor-cell migration. The RRL interactor optineurin contributes to this process by selectively binding myosin VI(short). Thus, the α2-linker acts like a molecular switch that assigns myosin VI to distinct endocytic (myosin VI(long)) or migratory (myosin VI(short)) functional roles.

Indexed as

Amino Acid SequenceCell Line, TumorCell MovementClathrinFemaleGene Knockout TechniquesHumansModels, MolecularMolecular Sequence DataMyosin Heavy ChainsNeoplasmsNuclear Magnetic Resonance, BiomolecularOvarian NeoplasmsProtein Interaction MapsProtein IsoformsProtein Structure, SecondaryClathrinMyosin Heavy Chainsmyosin VIProtein Isoforms

Identifiers

PMID26950368
PMCPMC4964928
OpenAlexW2293978630

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.